Drugs / IGV-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04485949 | Mar 2023 → Jan 2027 expected | glioblastoma | Imvax | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 12
| Date | Issuer | Release |
|---|---|---|
| 2026-09-15 | Imvax | Results Imvax Announces Additional Data from Phase 2b Clinical Trial of IGV-001 in Newly Diagnosed GBM and Provides Update on Planned Clinical Development imvax.com ↗
Top-line, prespecified analysis in patients with unmethylated MGMT newly diagnosed glioblastoma (ndGBM) suggests clinically meaningful improvement in overall survival, preservation of neurological function, and benefit to patient-reported outcomes |
| 2025-12-02 | Imvax | Results Imvax Announces Positive Top-line Data from Phase 2b Clinical Trial of IGV-001 in Newly Diagnosed GBM imvax.com ↗
The trial did not reach statistical significance on PFS but demonstrated a 6.3 month increase in median overall survival and a favorable safety profile. |
| 2024-05-21 | Imvax | Regulatory Imvax Announces Completion of Enrollment in Phase 2b Clinical Trial of IGV-001 and Successful Financing imvax.com ↗ |
| 2023-11-20 | Imvax | Results Imvax Presents New Data at 2023 SNO Annual Meeting Supporting its Lead Program, IGV-001, in Newly Diagnosed Glioblastoma imvax.com ↗
Additional data presented highlighted a significant decrease in the average neutrophil-to-lymphocyte (NLR) ratio at various study points. |
| 2023-08-08 | Imvax | Results Imvax Announces Publication in Journal for ImmunoTherapy of Cancer Showing IGV-001 Can Induce Clinically Relevant Anti-Cancer Immune Responses in Glioblastoma via Immunogenic Cell Death imvax.com ↗
IGV-001 can induce stress on glioblastoma cells within the product, resulting in immunogenic cell death and consequent broad anti-tumor immunity |
| 2023-04-17 | Imvax | Results Imvax Presents New Data at AACR 2023 Supporting the Mechanism of Action of its Lead Program, IGV-001, for Glioblastoma imvax.com ↗
IGV-001 preclinical studies show Goldspire ™ platform induces tumor cell death and release of an immunogenic payload correlated with enriched immune activity |
| 2022-11-10 | Imvax | Results Imvax Presents Preclinical Data at SITC 2022 Supporting Mechanism of Action and Anti-tumor Activity of its Immunotherapy Platform Across Multiple Tumor Types imvax.com ↗ |
| 2022-09-29 | Imvax | Results Imvax Presents New Data on Personalized Whole-Tumor Derived Immunotherapeutic Platform at 2022 International Cancer Immunotherapy Conference imvax.com ↗
This new data provides additional evidence for the generation of an immune response in the role of dendritic cell maturation, CD4 and CD8 T cell activation and increases in both central and effector memory T cells in the anti-tumor immunostimulatory activity of Imvax’s platform. |
| 2022-04-08 | Imvax | Results Imvax Presents New Data on Tumor-Derived Immunotherapies in Glioblastoma, Other Solid Tumors at AACR Annual Meeting 2022 imvax.com ↗
Predictive model of patient response to IGV-001 for glioblastoma developed based on Phase 1b clinical findings |
| 2021-11-09 | Imvax | Results Imvax Presents Data Showing Mechanisms for Broad Immune Activation by IGV-001 imvax.com ↗
The data from in vitro and in vivo studies highlight the effects of IGV-001 on inducing both innate and adaptive immune responses to tumor cells and point to the potential mechanism behind observed clinical activity for IGV-001 in the treatment of glioblastoma. |
| 2021-01-26 | Imvax | Results Imvax Announces Publication of Phase 1b Clinical Trial of IGV-001 for Patients with Newly Diagnosed Glioblastoma in Clinical Cancer Research imvax.com ↗
The optimal dose cohort demonstrated median progression-free survival at 17.1 months and median overall survival at just below 22 months. |
| 2019-03-31 | Imvax | Results Imvax Announces Positive Results from Clinical Trial of Novel IGV-001 Autologous Cell Vaccine in Treating Patients with Newly Diagnosed Glioblastoma imvax.com ↗
Median overall survival was 21.9 months for highest vaccine dose vs. 14.6 months i n published standard of care studies |
All press releases naming this drug 18 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IGV-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04485949 ↗ |
| Modality | Cell therapy | “autologous cell immunotherapy” NCT04485949 ↗ |
| Route | Other | “implanted with biodiffusion chambers containing IGV-001” NCT04485949 ↗ |